In prostate cancers, SFRP4 staining was seen in 4529 of our 6980 (64.9%) interpretable prostate cancers and was considered weak in 33.2%, moderate in 23.9%, strong in 7.8% of cancers. This evidence concerns the gene SFRP4 and prostate carcinoma.